ArticleMolecular & cellular proteomics : MCP2025
Transcriptomics and Proteomics Identify Serotonin Transporter as a Promising Therapeutic Target for Essential Tremor.
Article in Molecular & cellular proteomics : MCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Essential tremor (ET) stands as one of the most prevalent movement disorders originating from cerebellar dysfunction. However, effective treatment remains limited, largely due to a poor understanding of its molecular pathology. The harmaline-induced tremor in mice is a well-established model for ET research, though its mechanisms remain unclear. This study aimed to get insight into the molecular intricacies underlying cerebellar dysfunction in this model. Combining LC-MS/MS and RNA-Seq approach, we delved into the cerebellar alterations in harmaline-induced tremor in mouse. Multi-omics profiling identified 5194 correlated coding molecules, among which 19 were significantly dysregulated. Further KEGG enrichment analysis identified cerebellar serotonin transporter (SERT) as the key molecule in harmaline-induced tremor. We validated the upregulation of SERT in the cerebellar cortex following harmaline induction, particularly within Purkinje cells, and demonstrated that pharmacological inhibition or genetical knockdown of SERT significantly attenuated tremor severity and neuronal hyperexcitability. Further mechanistic studies revealed that harmaline-induced SERT upregulation leads to depleted serotonin levels in the cerebellum, contributing to tremor pathogenesis. In general, our study unveils crucial insights that could pave the way for molecular target identification and effective therapeutic interventions for ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.